ScripsAmerica's CEO Conducts Interview With Wall Street Newscast
NEW CASTLE, Del., Nov. 5, 2012 (GLOBE NEWSWIRE) -- ScripsAmerica Inc. (OTCBB:SCRC), a leading supplier of prescription, OTC and nutraceutical drugs, today announced that its CEO, Bob Schneiderman, has conducted an online interview with Wall Street Newscast regarding the Company's position and competitive advantages within the rapidly growing generic drug market.
A link to the interview can be found between ScripsAmerica's address and company description on the following page: www.wallstreetnewscast.com/profile/scrc.html.
The interview aims to inform current and potential investors about ScripsAmerica as a generic drug supplier and what the Company plans to accomplish in the coming fiscal year. Topics discussed in the interview include the $25 million US Government contract secured by the Company's pharmaceutical re-packager and acquisition target, Marlex Pharmaceuticals, the pending launch of ScripsAmerica's RapiMed product line of children's pain relievers and current financials.
Mr. Schneiderman also provides a very positive financial outlook for 2013 when ScripsAmerica anticipates significant revenue growth resulting from the combination of Marlex and its Government contracts being taken on by the Company, a successful RapiMed product launch and organic growth fueled by the increasing size of the generic drug market.
About Wall Street Newscast
Located in New York City, WallStreetNewscast.com (WSNC) has been providing Wall Street investor presentations for both public and private companies since 1998. WSNC offers a wide-range of services to companies and investor relation professionals to discuss their recent news announcements, earnings reports, and corporate events to a diverse network of individual and institutional investors on Wall Street. www.wallstreetnewscast.com
About ScripsAmerica, Inc.
ScripsAmerica, Inc. delivers pharmaceutical products to a wide range of end users across the health care industry through the largest pharmaceutical distributor in North America, McKesson Corporation. End users include retail pharmacies, hospitals, long-term care facilities and government and home care agencies. Current therapeutic categories serviced by the Company include pain, arthritis, prenatal, urinary, and hormonal replacement drugs. Other customers of ScripsAmerica include Cardinal Health, CutisPharma, Inc., MedVet and the United States Veterans Administration.
For more information, visit www.ScripsAmerica.com
Safe Harbor Statement
This release includes forward-looking statements, which are based on certain assumptions and reflects management's current expectations. These forward-looking statements are subject to a number of risks and uncertainties that could cause actual results or events to differ materially from current expectations. Some of these factors include: general global economic conditions; general industry and market conditions, sector changes and growth rates; uncertainty as to whether our strategies and business plans will yield the expected benefits; increasing competition; availability and cost of capital; the ability to identify and develop and achieve commercial success; the level of expenditures necessary to maintain and improve the quality of services; changes in the economy; changes in laws and regulations, including codes and standards, intellectual property rights, and tax matters; or other matters not anticipated; our ability to secure and maintain strategic relationships and distribution agreements. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.